



Proflora

FOOD SUPPLEMENT

PROVEN
ACTION

**PROMOTES THE BALANCE OF
INTESTINAL MICROBIOTA**

**ALIVE AND VIABLE GASTRO-PROTECTED
AND MICROENCAPSULATED PROBIOTIC STRAINS**

ENHANCED COLONY-FORMING PROBIOTIC ACTION

GLUTEN AND ALLERGEN FREE

 **Guna**
healthy lifestyle

The gut microbiota


Microbiota and intestine, the "hub" of human health

The qualitative-quantitative balance of the intestinal Microbiota, due to its close symbiosis with the cells of the GALT system (*Gut Associated Lymphoid Tissue*), is one of the fundamental players of the immune relationship between the mucous membranes of the MALT System (*Mucosa Associated Lymphoid Tissue*).^{1-2,3}

The loss of homeostasis in the qualitative-quantitative ratios of the Intestinal Microbiota is aetiologically correlated to episodes of Low-Grade Chronic Inflammation (LGCI) of the intestinal mucosa and to the consequent histological changes of the mucosa and of its main functions, becoming, often, the "primum movens" of the onset of various disorders, such as:⁴

- LGS (*Leaky Gut Syndrome*)
- IBS (*Irritable Bowel Syndrome*)
- IBD chronic (*Inflammatory Bowel Disease*)
- SIBO (*Small Intestinal Bacterial Overgrowth*)
- Intestinal motility disorders
- Diarrhea
- Dyspepsia
- Malabsorption
- Increased susceptibility to upper respiratory, gastrointestinal and urogenital infections
- Skin rashes
- Acne
- Allergies and food intolerance

Main eobiont bacterial groups that make up the intestinal microbiota



Bacterial and physiochemical interactions in different areas of the gastro-intestinal tract in adults (adapted from: Gibson and Rastell)

Maintaining the balance of the microbiota requires a broad-spectrum colony-forming action in view of a physiological replacement of the main eubiotic species in the bowel.

Proflora, symbiotic with proven colony-forming action, has the following characteristics⁵⁻⁶⁻⁷

Proflora - Ingredients

Proflora, symbiotic with clinically proven colony-forming eubiotic properties with 2 nuclei:

PROBIOTIC NUCLEUS

6 live and viable gastro-protected microencapsulated strains ⁶⁻⁷⁻⁸⁻⁹⁻¹⁰⁻¹¹⁻¹²⁻¹⁵

(5 strains of the Lactobacillus genus + 1 strain of the Bifidobacterium genus)

- » Bifidobacterium lactis BS01 > 1.00 billion
- » Lactobacillus rhamnosus LRO6 > 0.25 billion
- » Lactobacillus paracasei LPC00 > 0.25 billion
- » Lactobacillus acidophilus LA02 > 0.25 billion
- » Lactobacillus plantarum LPO2 > 0.25 billion
- » Lactobacillus salivarius LS03 > 0.02 billion

Higher survival

Clinical trials show a higher survival of gastro-protected and microencapsulated strains by up to 250% compared to non-microencapsulated strains.⁶⁻⁷

Colony-forming action

The action is balanced and proven for each individual strain up to 100% in different intestinal tracts, thanks to the new microencapsulation technology with vegetable fatty acids of food origin that protects probiotics against the aggressions of gastric pH and bile salts.⁶

This action is **enhanced 5 times compared to that of non gastro-protected strains** (2 billion/sachet of Proflora are equivalent to the colony-forming action of 10 billion non-gastro-protected strain/sachet).⁷

Excellent adhesiveness

The presence of Lactobacillus salivarius LS03 makes it easier for the probiotic strains to adhere to the intestinal mucosa.⁸

Ability to limit the spread of coliform bacteria (Escherichia coli)

The presence of Lactobacillus rhamnosus LRO6 and Lactobacillus plantarum LPO2 limits the spread of coliform bacteria.⁹⁻¹⁰⁻¹¹⁻¹²⁻¹³⁻¹⁴

Physiological balance of the Microbiota

Well-balanced replacement of the main eubiotic strains in the bowel, thanks to a physiological quantitative and qualitative ratio and the viability of the probiotic strains.

PREBIOTIC NUCLEUS

Short-chain fructo-oligosaccharides (FOS) from sugar beet that do not produce intestinal gas, **support the viability of the Microbiota**, selectively stimulate Lactobacilli and Bifidobacteria in the colon and support the **function of the intestinal barrier**, thus **reducing fermentation** episodes, with increased **mineral absorption**.¹⁵⁻¹⁶

Proflora is allergen free tested, patented by Probiotal S.p.A. according to current legislation (**Annex II Reg. EU 1169/2011**) for the following allergens: wheat, rye, barley, oats, spelt, kamut and kamut-derived strains, shellfish and shellfish products, eggs and egg products, fish and fish products, peanuts, soy and soy products, milk and dairy including lactose, nuts, celery, mustard, sesame seeds, lupins, mollusk and mollusk products, sulfur dioxide and sulphites at concentrations higher than 10 mg/kg or 10 mg/l expressed as sulfur dioxide.¹⁷





Coadministration of Lactobacillus and Bifidobacterium strains in combination with short-chain fructo-oligosaccharides reduces the ocular surface damage caused by dry eye syndrome (DED).

G.Chisari et Al.

Minerva Oftalmol. 2016 June;58(2):31-8

Summary: this clinical study was conducted to evaluate the effects of oral administration of Lactobacilli and Bifidobacteria, in association with fructo-oligosaccharides on the ocular surface of subjects with dry eye syndrome (DED). This study was conducted on 40 subjects with dry eye syndrome (DED) and symptoms related to: ocular discomfort, dry eye, burning sensation, foreign body sensation, itching. Patients were randomly divided into two groups: group A and group B (20 subjects per each group); subjects assigned to group A (control) were treated only with artificial tear substitutes (1 drop 3 times daily), while subjects treated in group B took a symbiotic (1 sachet of Proflora daily for a period of 30 days), in association with the treatment with artificial tear substitutes (1 drop 3 times daily). After a 5-day wash-out period, all clinical parameters were re-evaluated.

Results:



Conclusions: this study shows that food supplementation with a symbiotic with Lactobacilli and Bifidobacteria (Proflora) can be useful in improving DED with a significant strengthening of the defense systems of the ocular surface. These symbiotics show to have an important role in helping restore the intestinal ecosystem leading to the host's overall well-being.

The ocular ecosystem depends on the degree of the eco-biological functionality of the intestine and therefore of the GALT.



Proflora - Benefits and fields of use

Symbiotic and probiotic **action** in one single product

Probiotic colony-forming action is balanced, proven and enhanced⁶⁻⁷

Controlled stability and viability, with 100% colony-forming strains⁶⁻⁷

Support to the microbiota viability with prebiotic fibre (FOS)¹⁵⁻¹⁶

Gluten free

Allergen free¹⁷

Nutritional support in cases of: _____

- **Dysbiosis**
- **Gastro-intestinal disorders**
- **Malabsorption**
- **Food intolerance and adverse reactions to foods**
- **Tympanites**

Support to the intestinal flora balance in cases of: _____

- **Antibiotic and/or laxative treatments**
- **Diarrhea and bowel disorders**
- **Digestive disorders**
- **Irritable bowel syndrome**
- **Uro-genital infections**
- **Respiratory allergies**
- **Adverse reactions to foods**



Proflora IS THE **2nd** PILLAR OF INTESTINAL HOMEOSTASIS

1-REPAIR

Colostroni
with Noni
antioxidant properties

2-REPLACE

Proflora
support the
intestinal flora balance

3-REBALANCE

Gunabasic
contributes to normal
acid-base metabolism



Proflora + Colostroni

Microbiota balance and intestinal mucosa protection.



Colostroni:

24 x 1.8 g sachets of orodispersible granules
Net weight 43.2 g
with sweeteners

Proflora + Gunabasic

Microbiota balance and acid-base metabolism.



Gunabasic:

15 x 7 g sachets
Net weight 105 g
with sweetener

Proflora + Ferroguna

Microbiota balance and iron supplementation.



Ferroguna:

28 x 1.7 g sachets of orodispersible granules
Net weight 47.6 g
with sweeteners

Proflora + Gunaelmint

Microbiota balance in cases of helminth infestation.



Gunaelmint:

30 x 4.2 g sachets
Net weight 126 g
with sweetener

Proflora - Instructions for use

Instructions for use

DYSBIOSIS

Adults and children: recommended dose: 1 sachet daily for 30 days at least.

ACUTE GASTRO-INTESTINAL DISORDERS

Adults and children: recommended dose: 1 to 2 sachet/s daily for 8-10 days as prescribed by your doctor if needed. Afterwards, continue with 1 sachet daily for 30 days.

Proflora is also recommended for the elderly, for pregnant and breastfeeding women (as prescribed by doctor), for people affected by allergies, celiac disease, food intolerance or sensitization.

References

1. Thursby, E N Juge "Introduction to the human gut microbiota" *Biochem J.* 2017 Jun 1; 474(11): 1823-1836.
2. Bottazzi V et Al. "Il Microbiota Intestinale" *Pubblicazione Mofin Alce* 2009
3. Burcelin R. "Gut microbiota and immune crosstalk in metabolic disease" *Biol Aujourd'hui.* 2017;211(1):1-18. doi: 10.1051/jbio/2017008. Epub 2017 Jul 6.
4. Ray, BN Dittel "Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis" *Immunology.* 2015 Nov; 146(3):359-68. doi: 10.1111/imm.12511. Epub 2015 Sep 7.
5. Chisari G et Al. "La co-somministrazione dei ceppi batterici *Lactobacillus* e *Bifidobacterium* in associazione con frutto-oligosaccaridi a corta catena riduce il danno alla superficie oculare causata dalla sindrome dell'occhio secco (DED)". *Minerva Oftalmol.* 2016 June;58(2):31-8.
6. Del Piano M et Al. "Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains". *J Clin Gastroenterol.* 2010 Sep;44 Suppl 1:S42-6.
7. Del Piano M et Al. *In Vitro Sensitivity of Probiotics to Human Pancreatic Juice.* *J Clin Gastroenterol.* 2008; 42 (3): S170-173.
8. Neville BA, O'Toole PV. *Probiotic Properties of Lactobacillus salivarius and Closely Related Lactobacillus Species* *Future Microbiol.* 2010;5(5):759-774. https://www.medscape.com/viewarticle/722838_1
9. Bottazzi V et Al. "Il Microbiota Intestinale" *Pubblicazione Mofin Alce* 2009.
10. Deidda F et Al. "*L. rhamnosus* LR06 DSM 21981, *L. pentosus* LPS01 DSM 21980, *L. plantarum* LP01 LMG P-21021, *L. delbr.* subsp.
11. *Delbrueckii* LDD01 DSM 22106, *B. breve* BR03 DSM 16604 and *B. breve* B632 DSM 24706 strongly inhibit *in vitro* different *Escherichia coli* serotypes, including *E. coli* O157:H7" *J Clin Gastroenterol.* 2012 Ottobre; 46 Suppl:S85 - 92.
12. Poppi L B et Al. *Effect of Lactobacillus sp. isolates supernatant on Escherichia coli O157:H7 enhances the role of organic acids production as a factor for pathogen control.* *Pesq. Vet. Bras.* 35(4):353-359, Abril 2015 DOI: 10.1590/S0100-736X2015000400007.
13. J. Hirano et Al. *The effect of Lactobacillus rhamnosus on enterohemorrhagic Escherichia coli infection of human intestinal cells in vitro.* [HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/12906100"](https://www.ncbi.nlm.nih.gov/pubmed/12906100) *Microbiol Immunol.* 2003;47(6):405-9.
14. Adlerberth I et Al. *A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line ht-29 applied and environmental microbiology, July 1996, p. 2244-2251 vol. 62, no. 7 0099-2240/96/\$04.0010.*
15. Gibson GR, et AL. *Prebiotic effects: metabolic and health benefits.* *6"Br J Nutr.* 2010 Aug; 104 Suppl 2:S1-63.
16. Sheldon S Hendler et Al *PDR- Physicians Desk Reference ; 291-297; CEC Editore 2010* <https://doi.org/10.1152/ajpgi.1999.276.4.G941>
17. Mogna G et Al. *Allergen-free probiotics* *J Clin Gastroenterol.* 2008 Sep;42 Suppl 3 Pt 2:S201-4.
18. Vicariotto F, *La regola delle 3R nella nutraceutica fisiologica applicata all'asse "Intestino-Apparato urogenitale femminile,* *Nutrition & Health, GI Media, Supp n.5 2018 p 1-3.*

Proflora - Ingredients

Nutrition facts

	per 100 g	per sachet
Energy	1130 kJ 270 kcal	28.26 kJ 6.75 kcal
Fat of which saturates	0.7 g 0.31 g	17.6 mg 7.8 mg
Carbohydrate of which sugars	93.46 g 38.32 g	2.3 g 958 mg
Fibre	55.20 g	1.4 g
Protein	0.08 g	2 mg
Salt	0.04 g	1 mg
Bifidobacterium lactis BS01	> 40 B*	> 1.00 B
Lactobacillus rhamnosus LR06	> 10 B*	> 0.25 B
Lactobacillus paracasei LPC00	> 10 B*	> 0.25 B
Lactobacillus acidophilus LA02	> 10 B*	> 0.25 B
Lactobacillus plantarum LP02	> 10 B*	> 0.25 B
Lactobacillus salivarius LS03	> 0.8 B*	> 0.02 B
Fructo-oligosaccharides FOS	60 g	1500 mg

* The use of lactic acid bacteria strains in microencapsulated form makes it essential to apply, for the evaluation of the title in vital cells, the specific analytical method "Live cell count by cytofluorimetry", which is a validated variation of the official method ISO19344:2015. More information is available from Probiotical S.p.A.

One sachet of **Proflora** provides a daily intake of at least 2 billion lactic acid bacteria living cells. The content of the lactic acid bacteria strains is guaranteed until the expiry date indicated on the label, provided that the product is kept in its original and undamaged packaging.

Warnings

The expiry date refers to a product correctly stored in its original and undamaged packaging. Do not exceed the stated recommended daily dose. Keep out of the reach of young children. Food supplements should not be used as a substitute for a varied diet and a healthy lifestyle.

Ingredients

Fructo-oligosaccharides (FOS); Maltodextrin; Gastro-protected microencapsulated lactic acid bacteria strains: *Bifidobacterium lactis* BS01 (IMG P-21384), *Lactobacillus acidophilus* LA02 (DSM 21717), *Lactobacillus paracasei* LPC00 (IMG P-21380), *Lactobacillus plantarum* LP02 (IMG P-21020), *Lactobacillus rhamnosus* LR06 (DSM 21981), *Lactobacillus salivarius* LS03 (DSM 22776); Anti-caking agent: silicon dioxide.

Packaging

30 x 2.5 g sachets - Net weight 75 g e







GUNA S.p.a.
Via Palmanova, 71 - 20132
Milan - Italy
export@guna.it